Islet Management’s Orphazyme A/S ORPH Stock Holding History

Islet Management’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,353,768	Closed	-$14M	–	167
2020 Q3	$14M	Buy	+1,353,768	New	+$13.6M	0.96%	20

Other funds holding ORPH

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Islet Management's ORPH Position: Q4 2020 in Review

Islet Management sold out of Orphazyme A/S (ORPH) in Q4 2020, closing a stake of 1,353,768 shares — an estimated $14M sold.

Islet Management first reported a position in ORPH in Q3 2020 and held it in 1 quarter. The position peaked at $14M in Q3 2020. 5 funds tracked by Wall St. Rank hold ORPH as of Q4 2020.

Islet Management reported no remaining Orphazyme A/S position as of Q4 2020 after selling out during the quarter.
Islet Management sold 1,353,768 Orphazyme A/S shares in Q4 2020, an estimated $14M.
Islet Management first reported a position in Orphazyme A/S in Q3 2020 and held it in 1 quarter.
Islet Management's Orphazyme A/S position peaked at $14M in Q3 2020.
5 funds tracked by Wall St. Rank held Orphazyme A/S as of Q4 2020.

Based on Islet Management's 13F filing for Q4 2020, filed 16 Feb 2021.